ArticleScientific reports2025
Tenofovir attenuates cytokine storm and bronchiolar damage in a mouse model of bleomycin-induced acute lung injury.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cordycepin Alleviates Acute Lung Injury by Targeting TAK1 to Inhibit MAPK and NF-κB Signaling Pathways.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 pandemic has converged with the HIV epidemic. Although immunocompromised patients show an elevated risk of death due to COVID-19 compared to HIV infection, the impact remains contradictory. One reason could be the use of antiretroviral therapy (ARV). Patients with HIV receiving ARV, such as tenofovir (TDF), have fewer symptoms of COVID-19. In mice, bleomycin (BLM) induces acute lung injury, resulting in an acute inflammatory response similar to the cytokine storm and lung damage observed in COVID-19. This study aimed to evaluate the preventive role of TDF administration prior to BLM administration. A total of 64 eight-week-old C57BL/6J mice (Charles River, France), both male and female, were randomly assigned to four experimental groups (n = 8 per sex per group): (i) oral TDF administered in drinking water from day 0 to day 7, followed by oropharyngeal aspiration (OA) of saline on day 7 (TDF); (ii) oral TDF in drinking water from day 0 to day 7, followed by OA of bleomycin on day 7 (TDF-BLM); (iii) regular drinking water throughout the experiment, followed by OA of saline on day 7 (SAL); and (iv) regular drinking water throughout the experiment, followed by OA of bleomycin on day 7 (BLM). Animals were euthanized 72 h after OA (day 10), and serum and lung tissues were collected for analysis. TDF-BLM lungs showed significantly reduced bronchioalveolar lavage fluid total cell counts, specifically reduced macrophages and neutrophils counts, but an increased presence of minority lymphocytes. TDF downregulated BLM-induced levels of Il1β, Il6, TNFα, and Tgfβ mRNA. Preventive treatment with TDF counteracted BLM-induced alveolar and bronchiolar cell damage. Male mice showed more severe symptoms after BLM administration for most parameters, and the preventive action of TDF was similar in both sexes. Preventive TDF administration partially counteracted BLM-induced acute lung injury. These findings support epidemiological observations suggesting a potential benefit of TDF as a prophylactic therapy against COVID-19, at least in HIV-infected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.